Kevin Blansit, Other
Research Associate
Palo Alto Medical Foundation Research Institute
795 El Camino Real
Palo Alto,
CA
USA
94301
Papers:
128
Disease stabilization vs. response after bevacizumab treatment in recurrent ovarian cancer: how do we determine clinical efficacy?
180
The increase in early detection and associated improved survival of cervical cancer in the US: a ten-year study of 6,414 patients
190
Trends in FDA approval of oncology drugs: have we made progress?
209
Correlation between type I uterine cancer and diet and lifestyle in US-born versus immigrant Asian subgroups
211
Types of surgery for morbidly obese endometrial cancer patients in the US: how and where do we make the largest impact?
212
Differences in survival between clear cell uterine and ovarian carcinoma patients
385
Differences in BMI and physical activity in Whites vs. Asians in California in association with type I uterine cancer